Revised: 12/2014 Inhalation Solution: 2.5 mg/2.5 ml in single-use ampules (3)

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Revised: 12/2014 Inhalation Solution: 2.5 mg/2.5 ml in single-use ampules (3)"

Transcription

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PULMOZYME safely and effectively. See full prescribing information for PULMOZYME. PULMOZYME (dornase alfa) inhalation solution, for inhalation use Initial U.S. Approval: RECENT MAJOR CHANGES Dosage and Administration (2.2) 12/ INDICATIONS AND USAGE PULMOZYME is a recombinant DNase enzyme indicated in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. (1) DOSAGE AND ADMINISTRATION The recommended dosage is one 2.5 mg single-use ampule inhaled once daily using a recommended nebulizer. (2.1) Some patients may benefit from twice daily administration. (2.1) CONTRAINDICATIONS PULMOZYME is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product. (4) WARNINGS AND PRECAUTIONS None ADVERSE REACTIONS The most common adverse reactions (occurring in 3% of patients treated with PULMOZYME over placebo) seen in clinical trials in CF patients were: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of 10%, fever, and dyspnea. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Genentech at or FDA at FDA-1088 or See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling DOSAGE FORMS AND STRENGTHS Revised: 12/2014 Inhalation Solution: 2.5 mg/2.5 ml in single-use ampules (3) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Directions for Use 2.3 Storage and Handling 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION *Sections or subsections omitted from the full prescribing information are not listed. 1

2 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE PULMOZYME (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. In CF patients with an FVC 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage The recommended dosage for use in most cystic fibrosis patients is one 2.5 mg single-use ampule inhaled once daily using a recommended jet nebulizer/compressor system or erapid Nebulizer System. Some patients may benefit from twice daily administration [see Clinical Studies (14)] 2.2 Directions for Use Administer PULMOZYME via the erapid Nebulizer System or via a jet nebulizer connected to an air compressor with an adequate air flow and equipped with a mouthpiece or suitable face mask (see Table 1). No data are currently available to support the administration of PULMOZYME with other nebulizer systems. Do not dilute or mix PULMOZYME with other drugs in the nebulizer. Mixing of PULMOZYME with other drugs could lead to adverse physicochemical and/or functional changes in PULMOZYME or the admixed compound. Table 1 Recommended Jet Nebulizers/Compressors and Nebulizer Systems Jet Nebulizer Compressor Hudson T Up-draft II with Pulmo-Aide Marquest Acorn II with Pulmo-Aide PARI LC Plus with PARI PRONEB **PARI BABY with PARI PRONEB Durable Sidestream with MOBILAIRE Durable Sidestream with Porta-Neb Nebulizer System erapid Nebulizer System* *Consisting of the erapid Nebulizer Handset with ebase Controller. **Patients who are unable to inhale or exhale orally throughout the entire nebulization period may use the PARI BABY nebulizer. 2

3 The patient should follow the manufacturer's instructions on the use and maintenance of the equipment, including cleaning and disinfection procedures. When PULMOZYME is administered with the erapid Nebulizer System, advise patients to replace the handset after 90 uses, regardless of whether the EasyCare cleaning aid is used. Since delivery data are not available for PULMOZYME administered with the erapid handset beyond 90 administrations, delivery of the appropriate therapeutic dose of PULMOZYME cannot be assured beyond 90 administrations. The erapid Nebulizer System should only be used by adults and children who can use a mouthpiece, and not by younger children who need a mask to take PULMOZYME. 2.3 Storage and Handling Store PULMOZYME ampules in their protective foil pouch under refrigeration and protected from light. Refrigerate ampules during transport and do not expose to room temperatures for a total time of 24 hours. Each PULMOZYME ampule should be squeezed prior to use in order to check for leaks. Discard ampules if the solution is cloudy or discolored. Once opened, the entire contents of the ampule must be used or discarded. 3 DOSAGE FORMS AND STRENGTHS Inhalation Solution: 2.5 mg/2.5 ml in single-use ampules. 4 CONTRAINDICATIONS PULMOZYME is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product. 5 WARNINGS AND PRECAUTIONS None. 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to PULMOZYME in 902 patients, with exposures ranging from 2 weeks of daily administration up to once or twice daily administration for six months. PULMOZYME was studied in both placebo-controlled and uncontrolled trials (n=804 and n=98). The population of patients in placebo-controlled trials was with FVC 40% of predicted (n=643) or with more advanced pulmonary disease, FVC < 40% of predicted (n=161). The population in the uncontrolled trial included 98 pediatric patients with CF ranging from 3 months to 10 years of age. More than half of the patients received PULMOZYME 2.5 mg by inhalation once a day (n=581), while the rest of patients (n=321) received PULMOZYME 2.5 mg by inhalation twice a day. 3

4 Placebo-Controlled Trials Trial 1: Trial 1 was a randomized, placebo-controlled clinical trial in patients with FVC 40% of predicted. In this trial, over 600 patients received PULMOZYME once or twice daily for six months. The most common adverse reaction (risk difference 5%) was voice alteration. The proportion of most adverse events was similar for patients on PULMOZYME and on placebo, probably reflecting the sequelae of the underlying lung disease. In most cases reactions that were increased were mild, transient in nature, and did not require alterations in dosing. Few patients experienced adverse reactions resulting in permanent discontinuation from PULMOZYME, and the proportion of discontinuations were similar for placebo (2%) and PULMOZYME (3%). Adverse reactions occurring in a higher proportion (greater than 3%) of PULMOZYME treated patients than in placebo-treated patients are listed in Table 2. Trial 2: Trial 2 was a randomized, placebo-controlled trial in patients with more advanced pulmonary disease (FVC < 40% of predicted) who were treated for 12 weeks. In this trial, the safety profile of PULMOZYME was similar to that reported in patients with less advanced pulmonary disease (FVC 40% of predicted). Adverse reactions that were reported in this trial with a higher proportion (greater than 3%) in the PULMOZYME treated patients are listed in Table 2. 4

5 Table 2. Adverse Reactions Increased 3% or More in PULMOZYME Treated Patients Over Placebo in CF Clinical Trials Adverse Reactions (of any severity or seriousness) Trial 1 CF Patients with FVC 40% of predicted treated for 24 weeks Placebo n=325 Pulmozyme QD n=322 Pulmozyme BID n=321 Trial 2 CF Patients with FVC <40% of predicted treated for 12 weeks Placebo n=159 Pulmozyme QD n=161 Voice alteration 7% 12% 16% 6% 18% Pharyngitis 33% 36% 40% 28% 32% Rash 7% 10% 12% 1% 3% Laryngitis 1% 3% 4% 1% 3% Chest Pain 16% 18% 21% 23% 25% Conjunctivitis 2% 4% 5% 0% 1% Rhinitis FVC decrease of 10% of predicted Differences were less than 3% 24% 30% 17% 22% Fever 28% 32% Dyspepsia 0% 3% Dyspnea (when reported as serious) Differences were less than 3% 12% 17% Single measurement only, does not reflect overall FVC changes. Total reports of dyspnea (regardless of severity or seriousness) had a difference of less than 3% in Trial 2. Mortality rates observed in controlled trials were similar for the placebo and PULMOZYME treated patients. Causes of death were consistent with progression of cystic fibrosis and included apnea, cardiac arrest, cardiopulmonary arrest, cor pulmonale, heart failure, massive hemoptysis, pneumonia, pneumothorax, and respiratory failure. Uncontrolled Trial Trial 3: The safety of PULMOZYME, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 98 pediatric patients with cystic fibrosis 3 months to 10 years of age (65 aged 3 months to < 5 years, 33 aged 5 to 10 years). The PARI BABY reusable nebulizer (which uses a facemask instead of a mouthpiece) was utilized in patients unable to demonstrate the ability to inhale or exhale orally throughout the entire treatment period (54/65, 83% of the younger and 2/33, 6% of the older patients). Overall, the nature of adverse reactions was similar to that seen in the placebo-controlled trials. The number of patients reporting cough was higher in the younger age group as compared to the older age group (29/65, 45% compared to 10/33, 30%) as was the number reporting moderate to severe cough (24/65, 37% as compared to 6/33, 18%). The number of patients reporting rhinitis was higher in the 5

6 younger age group as compared to the older age group (23/65, 35% compared to 9/33, 27%) as was the number reporting rash (4/65, 6% as compared to 0/33). Allergic Reactions There have been no reports of anaphylaxis attributed to the administration of PULMOZYME. Urticaria, mild to moderate, and mild skin rash have been observed and have been transient. Within all of the studies, a small percentage (average of 2-4%) of patients treated with PULMOZYME developed serum antibodies to PULMOZYME. None of these patients developed anaphylaxis, and the clinical significance of serum antibodies to PULMOZYME is unknown. 6.2 Postmarketing Experience Postmarketing spontaneous reports and prospectively collected safety data from observational studies confirm the safety profile to be as described in clinical trials [see Adverse Reactions (6.1)]. 7 DRUG INTERACTIONS Available data indicate there are no clinically important drug-drug interactions with PULMOZYME. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk summary There are no adequate and well-controlled studies with PULMOZYME in pregnant women. However, animal reproduction studies have been conducted with dornase alfa. In these studies, no evidence of fetal harm was observed in rats and rabbits at doses of dornase alfa up to approximately 600 times the maximum recommended human dose (MRHD). The background risk of major birth defects and miscarriage for the cystic fibrosis population is unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data Reproductive studies have been performed in rats and rabbits at intravenous doses of dornase alfa up to 10 mg/kg/day (approximately 600 times the MRHD in adults). In a combined embryo-fetal development and pre- and post-natal development study, no evidence of maternal toxicity, embryotoxicity, or teratogenicity was observed when dornase alfa was administered to dams throughout organogenesis (Gestation days 6 to 17). Dornase alfa did not elicit adverse effects on fetal or neonatal growth when administered to dams throughout most of gestation and delivery (Gestation days 6 to 25) and nursing (Post-partum days 6 to 21). A pharmacokinetic study in Cynomolgus monkeys found no detectable levels of dornase alfa in fetal blood or amniotic fluid on gestation day 150 (end of gestation) from mothers that were administered an intravenous bolus dose (0.1 mg/kg) followed by an intravenous infusion dose (0.080 mg/kg) over a 6-hour period during pregnancy. 6

7 8.2 Lactation Risk Summary It is not known whether PULMOZYME is present in human milk. In a pharmacokinetic study in Cynomolgus monkeys, levels of dornase alfa detected in milk were less than 0.1% of the maternal serum concentration at 24 hours after dosing [intravenous bolus dose (0.1 mg/kg) of dornase alfa followed by an intravenous infusion (0.080 mg/kg/hr) over a 6-hour period] on post-partum day 14. The developmental and health benefits of breastfeeding should be considered along with the mother s clinical need for PULMOZYME and any potential adverse effects on the breastfed child from PULMOZYME or from the underlying maternal condition. 8.4 Pediatric Use The safety and effectiveness of PULMOZYME have been established in pediatric patients 5 years of age and older [see Adverse Reactions (6) and Clinical Studies (14)]. The safety of PULMOZYME, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 65 patients with cystic fibrosis aged 3 months to < 5 years [see Adverse Reactions (6.1)]. While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in pulmonary function or who may be at risk of respiratory tract infection. 8.5 Geriatric Use Cystic fibrosis is primarily a disease of children and young adults. Clinical studies of PULMOZYME did not include sufficient numbers of subjects aged 65 or older to determine whether they respond differently from younger subjects. 10 OVERDOSAGE Single-dose inhalation studies in rats and monkeys at doses up to 180-times higher than doses routinely used in clinical studies are well tolerated. Single dose oral administration of PULMOZYME in doses up to 200 mg/kg are also well tolerated by rats. Cystic fibrosis patients have received up to 20 mg BID for up to 6 days and 10 mg BID intermittently (2 weeks on/2 weeks off drug) for 168 days. These doses were well tolerated. 11 DESCRIPTION PULMOZYME is a recombinant human deoxyribonuclease I (rhdnase) an enzyme which selectively cleaves DNA. The protein is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing DNA encoding for the native human protein, deoxyribonuclease I (DNase). Fermentation is carried out in a nutrient medium containing the antibiotic gentamicin, mg/l. However, the presence of the antibiotic is not detectable in the final product. The product is purified by tangential flow filtration and column chromatography. The purified glycoprotein contains 260 amino acids with an approximate molecular weight of 37,000 daltons. The primary amino acid sequence is identical to that of the native human enzyme. PULMOZYME is administered by inhalation of an aerosol mist produced by a compressed air driven nebulizer or an approved nebulizer system [see Clinical Studies (14) and Dosage and Administration (2)]. 7

8 PULMOZYME is a sterile, clear, colorless, highly purified solution in single-use ampules. Each ampule delivers 2.5 ml of the solution to the nebulizer bowl. Each ml of aqueous solution contains 1 mg dornase alfa, calcium chloride dihydrate (0.15 mg) and sodium chloride (8.77 mg). The solution contains no preservative. The nominal ph of the solution is CLINICAL PHARMACOLOGY 12.1 Mechanism of Action PULMOZYME is recombinant human deoxyribonuclease I (rhdnase), an enzyme which selectively cleaves DNA. In preclinical in vitro studies, PULMOZYME hydrolyzes the DNA in sputum of CF patients and reduces sputum viscoelasticity. In CF patients, retention of viscous purulent secretions in the airways contributes both to reduced pulmonary function and to exacerbations of infection. Purulent pulmonary secretions contain very high concentrations of extracellular DNA released by degenerating leukocytes that accumulate in response to infection Pharmacokinetics When 2.5 mg PULMOZYME was administered by inhalation to eighteen CF patients, mean sputum concentrations of 3 µg/ml DNase were measurable within 15 minutes. Mean sputum concentrations declined to an average of 0.6 µg/ml two hours following inhalation. Inhalation of up to 10 mg TID of PULMOZYME by 4 CF patients for six consecutive days, did not result in a significant elevation of serum concentrations of DNase above normal endogenous levels. After administration of up to 2.5 mg of PULMOZYME twice daily for six months to 321 CF patients, no accumulation of serum DNase was noted. Dornase alfa is expected to be metabolized by proteases present in biological fluids. A human intravenous dose study suggested an elimination half-life of 3-4 hours for dornase alpha. PULMOZYME, 2.5 mg by inhalation, was administered daily to 98 patients aged 3 months to 10 years, and bronchoalveolar lavage (BAL) fluid was obtained within 90 minutes of the first dose. BAL DNase concentrations were detectable in all patients but showed a broad range, from to 1.8 µg/ml. Over an average of 14 days of exposure, serum DNase concentrations (mean ± s.d.) increased by 1.1 ± 1.6 ng/ml for the 3 months to < 5 year age group and by 0.8 ± 1.2 ng/ml for the 5 to 10 year age group. The relationship between BAL or serum DNase concentration and adverse experiences and clinical outcomes is unknown. 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility PULMOZYME produced no treatment-related increases in the incidence of tumors in a lifetime study in Sprague Dawley rats that were administered inhaled doses up to mg/kg/day (approximately 30 times the MRHD in adults). There was no increase in the development of benign or malignant neoplasms and no occurrence of unusual tumor types in rats after lifetime exposure. PULMOZYME tested negative in the following genotoxicity assays: the in vitro Ames assay, in vitro mouse lymphoma assay, and in vivo mouse bone marrow micronucleus assay. No evidence of impairment of fertility was observed in male and female rats that received intravenous doses up to 10 mg/kg/day (approximately 600 times the MRHD in adults). 8

9 14 CLINICAL STUDIES Trial in CF Patients with FVC >40% of Predicted PULMOZYME has been evaluated in a randomized, placebo-controlled trial of clinically stable cystic fibrosis patients, 5 years of age and older, with baseline forced vital capacity (FVC) greater than or equal to 40% of predicted and receiving standard therapies for cystic fibrosis. Patients were treated with placebo (325 patients), 2.5 mg of PULMOZYME once a day (322 patients), or 2.5 mg of PULMOZYME twice a day (321 patients) for six months administered via a Hudson T Up-draft II nebulizer with a Pulmo-Aide compressor. Both doses of PULMOZYME resulted in significant reductions in the number of patients experiencing respiratory tract infections requiring use of parenteral antibiotics compared with the placebo group. Administration of PULMOZYME reduced the relative risk of developing a respiratory tract infection by 27% and 29% for the 2.5 mg daily dose and the 2.5 mg twice daily dose, respectively (see Table 3). The data suggest that the effects of PULMOZYME on respiratory tract infections in older patients ( > 21 years) may be smaller than in younger patients, and that twice daily dosing may be required in the older patients. Patients with baseline FVC > 85% may also benefit from twice a day dosing (see Table 3). The reduced risk of respiratory infection observed in PULMOZYME treated patients did not directly correlate with improvement in FEV 1 during the initial two weeks of therapy. Within 8 days of the start of treatment with PULMOZYME, mean FEV 1 increased 7.9% in those treated once a day and 9.0% in those treated twice a day compared to the baseline values. The overall mean FEV 1 during long-term therapy increased 5.8% from baseline at the 2.5 mg daily dose level and 5.6% from baseline at the 2.5 mg twice daily dose level. Placebo recipients did not show significant mean changes in pulmonary function testing (see Figure 1). For patients 5 years of age or older, with baseline FVC greater than or equal to 40%, administration of PULMOZYME decreased the incidence of occurrence of first respiratory tract infection requiring parenteral antibiotics, and improved mean FEV 1, regardless of age or baseline FVC. 9

10 Table 3. Incidence of First Respiratory Tract Infection Requiring Parenteral Antibiotics in Patients with FVC 40% of Predicted Placebo N= mg QD N= mg BID N=321 Percent of Patients Infected 43% 34% 33% Relative Risk (vs placebo) p-value (vs placebo) Subgroup by Age and Baseline FVC Age Placebo % (N) 2.5 mg QD % (N) 2.5 mg BID % (N) 5-20 years 42% (201) 25% (199) 28% (184) 21 years and older 44% (124) 48% (123) 39% (137) Baseline FVC 40-85% Predicted 54% (194) 41% (201) 44% (203) > 85% Predicted 27% (131) 21% (121) 14% (118) Figure 1. Mean Percent Change from Baseline FEV 1 in Patients with FVC 40% of Predicted Trial in CF Patients with FVC <40% of Predicted PULMOZYME has also been evaluated in a second randomized, placebo-controlled trial in clinically stable patients with baseline FVC < 40% of predicted. Patients were enrolled and treated with placebo (162 patients) or PULMOZYME 2.5 mg QD (158 patients) for twelve weeks. In patients who received PULMOZYME, there was an increase in mean change (as percent of baseline) compared to placebo in FEV 1 (9.4% vs. 2.1%, p < 0.001) and in FVC (12.4% vs. 7.3%, p < 0.01). PULMOZYME did not significantly reduce the risk of developing a respiratory tract infection requiring parenteral antibiotics 10

11 (54% of PULMOZYME patients vs. 55% of placebo patients had experienced a respiratory tract infection by 12 weeks, relative risk =.93, p = 0.62). The effect of PULMOZYME on exercise tolerance has not been established in adult and pediatric patients. Other Studies Clinical trials have indicated that PULMOZYME therapy can be continued or initiated during an acute respiratory exacerbation. Short-term dose ranging studies demonstrated that doses in excess of 2.5 mg BID did not provide further improvement in FEV 1. Patients who have received drug on a cyclical regimen (i.e., administration of PULMOZYME 10 mg BID for 14 days, followed by a 14 day wash out period) showed rapid improvement in FEV 1 with the initiation of each cycle and a return to baseline with each PULMOZYME withdrawal. 16 HOW SUPPLIED/STORAGE AND HANDLING PULMOZYME is supplied in: 30 unit cartons containing 5 foil pouches of 6 single-use ampules. Each 2.5 ml ampule contains 2.5 mg of dornase alpha (1 mg/ml): NDC Storage and Handling Store PULMOZYME under refrigeration (2 C to 8 C/36 F to 46 F) in their protective foil to protect from light. Do not use beyond the expiration date stamped on the ampule. Store unused ampules in their protective foil pouch under refrigeration. Refrigerate PULMOZYME during transport and do not expose to room temperatures for a total time of 24 hours. 17 PATIENT COUNSELING INFORMATION Advise patients to read the FDA-approved Patient Labeling (Instructions for Use) Storage and Handling Information Instruct patients on the proper techniques to store and handle PULMOZYME. PULMOZYME must be stored in the refrigerator at 2 to 8 C (36 to 46 F) and protected from light. It should be kept refrigerated during transport and should not be exposed to room temperatures for a total time of 24 hours. Advise patients to squeeze each ampule prior to use in order to check for leaks. The solution should be discarded if it is cloudy or discolored. Once opened, the entire contents of the ampule must be used or discarded. Instruct patients in the proper use and maintenance of the jet nebulizer/compressor system or erapid Nebulizer System used in PULMOZYME delivery. Instruct patients not to dilute or mix PULMOZYME with other drugs in the nebulizer. Mixing of PULMOZYME with other drugs could lead to adverse physicochemical and/or functional changes in PULMOZYME or the admixed compound. 11

12 Use with the erapid Nebulizer System Instruct patients and caregivers to read and follow the directions in both the PULMOZYME Instructions for Use and in the Manufacturer s erapid Nebulizer System Instruction Booklet. Instruct patients and caregivers to clean the handset, including the medication reservoir, medicine cap, aerosol head, and mouthpiece, after each use. Instruct patients and caregivers to disinfect the handset, including the medication reservoir, medicine cap, aerosol head, and mouthpiece, after each day of use. Instruct patients to replace the handset after 90 uses, regardless of whether the EasyCare cleaning aid is used. Since delivery data are not available for PULMOZYME administered with the erapid handset beyond 90 administrations, delivery of the appropriate therapeutic dose of PULMOZYME cannot be assured beyond 90 administrations. Pulmozyme (dornase alfa) Inhalation Solution Manufactured by: Genentech, Inc. A Member of the Roche Group 1 DNA Way South San Francisco, CA US License No Genentech, Inc. All rights reserved 2014 Genentech, Inc. Pulmozyme is a trademark of Genentech, Inc. 12

Instructions for Use. PULMOZYME (PULL-muh-zyme) (dornase alfa) Inhalation Solution. Instructions for Use with Jet Nebulizers and Compressors

Instructions for Use. PULMOZYME (PULL-muh-zyme) (dornase alfa) Inhalation Solution. Instructions for Use with Jet Nebulizers and Compressors Instructions for Use PULMOZYME (PULL-muh-zyme) (dornase alfa) Inhalation Solution Instructions for Use with Jet Nebulizers and Compressors See the other side of this Instructions for Use for information

More information

RESTASIS (cyclosporine ophthalmic emulsion) 0.05% Initial U.S. Approval: 1983

RESTASIS (cyclosporine ophthalmic emulsion) 0.05% Initial U.S. Approval: 1983 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RESTASIS 0.05% safely and effectively. See full prescribing information for RESTASIS. RESTASIS (cyclosporine

More information

DOSAGE FORMS AND STRENGTHS Cyclosporine ophthalmic emulsion 0.5 mg/ml (3)

DOSAGE FORMS AND STRENGTHS Cyclosporine ophthalmic emulsion 0.5 mg/ml (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RESTASIS MULTIDOSE TM safely and effectively. See full prescribing information for RESTASIS MULTIDOSE

More information

CONTRAINDICATIONS None. (4) OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% Initial U.S. Approval: 2014

CONTRAINDICATIONS None. (4) OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3% Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OMIDRIA safely and effectively. See full prescribing information for OMIDRIA. OMIDRIA (phenylephrine

More information

Information for Patients Safety Information. TOBI Packaging. Dosage. Treatment Schedule. How To Administer TOBI

Information for Patients Safety Information. TOBI Packaging. Dosage. Treatment Schedule. How To Administer TOBI Nebulizer Solution For Inhalation Use Only Information for Patients Safety Information TOBI is in a class of antibiotics that have caused hearing loss, dizziness, kidney damage, and harm to a fetus. Ringing

More information

Learn More About Product Labeling

Learn More About Product Labeling Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific

More information

Selected Requirements of Prescribing Information

Selected Requirements of Prescribing Information The Selected Requirements of Prescribing Information (SRPI) is a checklist of 42 important format prescribing information (PI) items based on labeling regulations [21 CFR 201.56(d) and 201.57] and guidances.

More information

DO YOU HAVE ITCHY ALLERGY EYES? Find out about lasting relief

DO YOU HAVE ITCHY ALLERGY EYES? Find out about lasting relief DO YOU HAVE ITCHY ALLERGY EYES? Find out about lasting relief Common causes of itching due to eye allergies include: Pollen from trees, grasses, and ragweed Dust mites Cat dander Approximately 10 million

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ACULAR safely and effectively. See full prescribing information for ACULAR. ACULAR (ketorolac tromethamine

More information

ZOVIRAX Cold Sore Cream

ZOVIRAX Cold Sore Cream Data Sheet ZOVIRAX Cold Sore Cream Aciclovir 5% w/w Presentation Topical cream Indications ZOVIRAX Cold Sore Cream is indicated for the treatment of Herpes simplex virus infections of the lips and face

More information

Page 1 of 19. * Sections or subsections omitted from the full prescribing information are not listed. Diluent (0.17% sodium chloride): 1 ml/ampule (3)

Page 1 of 19. * Sections or subsections omitted from the full prescribing information are not listed. Diluent (0.17% sodium chloride): 1 ml/ampule (3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CAYSTON safely and effectively. See full prescribing information for CAYSTON. CAYSTON (aztreonam

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR

See 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2016 FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYSODREN safely and effectively. See full prescribing information for LYSODREN. LYSODREN (mitotane)

More information

Billing and Coding Guide

Billing and Coding Guide Billing and Coding Guide INDICATIONS Injectafer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to or have had unsatisfactory

More information

8.5 Geriatric Use * Sections or subsections omitted from the full prescribing information are not listed.

8.5 Geriatric Use * Sections or subsections omitted from the full prescribing information are not listed. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Injectafer safely and effectively. See full prescribing information for Injectafer. INJECTAFER (ferric

More information

PATIENT INFORMATION. CAYSTON (kay-stun) (aztreonam for inhalation solution)

PATIENT INFORMATION. CAYSTON (kay-stun) (aztreonam for inhalation solution) PATIENT INFORMATION CAYSTON (kay-stun) (aztreonam for inhalation solution) Read this Patient Information before you start taking CAYSTON and each time you get a refill. This information does not take the

More information

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor)

Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) EMA/662624/2015 Summary of the risk management plan (RMP) for Orkambi (lumacaftor and ivacaftor) This is a summary of the risk management plan (RMP) for Orkambi, which details the measures to be taken

More information

Sodium Chloride Injection, USP

Sodium Chloride Injection, USP Sodium Chloride Injection, USP Flexible Plastic Container Rx only DESCRIPTION Sodium Chloride Injection, USP solutions are sterile and nonpyrogenic. They are parenteral solutions containing various concentrations

More information

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Summary of the risk management plan (RMP) for Ofev (nintedanib) EMA/738120/2014 Summary of the risk management plan (RMP) for Ofev (nintedanib) This is a summary of the risk management plan (RMP) for Ofev, which details the measures to be taken in order to ensure that

More information

Indicated for flu treatment for ages 2 weeks and older

Indicated for flu treatment for ages 2 weeks and older DOSAGE AND ADMINISTRATION IN ADULT AND PEDIATRIC PATIENTS Please see Important Safety Information on pages 6 8. Indicated for flu treatment for ages 2 weeks and older Available in 30-mg, 45-mg, and 75-mg

More information

HIGHLIGHTS OF PRESCRIBING INFORMATION

HIGHLIGHTS OF PRESCRIBING INFORMATION 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for TALTZ. TALTZ (ixekizumab) injection,

More information

Colistin for Nebulisation

Colistin for Nebulisation Colistin for Nebulisation SCG: For the treatment of Pseudomonas aeruginosa lung infections AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE The following guidelines are designed to provide information relating

More information

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been

More information

WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS Pursue more moments LONSURF (trifluridine and tipiracil) is a prescription medicine used to treat people with colon or rectal cancer that has spread to other parts of the body and who have been previously

More information

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products

IMPORTANT DRUG WARNING Regarding Mycophenolate-Containing Products Dear Healthcare Provider: Mycophenolate REMS (Risk Evaluation and Mitigation Strategy) has been mandated by the FDA (Food and Drug Administration) due to postmarketing reports showing that exposure to

More information

FULL PRESCRIBING INFORMATION: CONTENTS*

FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHOTREXA VISCOUS and PHOTREXA safely and effectively. See full prescribing information for PHOTREXA

More information

SUMMARY OF PRODUCT CHARACTERISTICS. One gram of suspension contains 10 mg fusidic acid (as hemihydrate).

SUMMARY OF PRODUCT CHARACTERISTICS. One gram of suspension contains 10 mg fusidic acid (as hemihydrate). SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fucithalmic 10 mg/g eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of suspension contains 10 mg fusidic acid

More information

BETHKIS (Tobramycin Inhalation Solution) Initial U.S. Approval: 1980

BETHKIS (Tobramycin Inhalation Solution) Initial U.S. Approval: 1980 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BETHKIS safely and effectively. See full prescribing information for BETHKIS. BETHKIS (Tobramycin

More information

POLYTRIM (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) Sterile

POLYTRIM (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) Sterile POLYTRIM (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) Sterile DESCRIPTION POLYTRIM (polymyxin B sulfate and trimethoprim ophthalmic solution, USP) is a sterile antimicrobial solution

More information

Revised: 9/2014. LUMIGAN (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use. Initial U.S. Approval: 2001

Revised: 9/2014. LUMIGAN (bimatoprost ophthalmic solution) 0.01% for topical ophthalmic use. Initial U.S. Approval: 2001 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LUMIGAN (bimatoprost ophthalmic solution) 0.01% safely and effectively. See full prescribing information

More information

Clinical Trials Glossary

Clinical Trials Glossary Clinical Trials Glossary ADME: an acronym for absorption, distribution, metabolism and elimination. ADME studies determine how a drug is absorbed by the body, the chemical changes that it may undergo and

More information

Reference ID: 3482803

Reference ID: 3482803 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EVZIO safely and effectively. See full prescribing information for EVZIO. EVZIO (naloxone hydrochloride

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SORILUX safely and effectively. See full prescribing information for SORILUX. SORILUX (calcipotriene)

More information

1 INDICATIONS AND USAGE

1 INDICATIONS AND USAGE HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Calcium Acetate Capsules safely and effectively. See full prescribing information for Calcium Acetate

More information

Clinical Manifestations of Adverse Reactions. Definitions and Classifications. Exaggerated Effect on Target Tissues

Clinical Manifestations of Adverse Reactions. Definitions and Classifications. Exaggerated Effect on Target Tissues Chapter 3 Outline Chapter 3: Adverse reactions Definitions and classifications Clinical manifestations of adverse reactions Toxicologic evaluation of drugs 2 Haveles (p. 28) Drugs may act on biologic systems

More information

Summary of the risk management plan (RMP) for Cerdelga (eliglustat)

Summary of the risk management plan (RMP) for Cerdelga (eliglustat) EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to

More information

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP PRESCRIBING INFORMATION 3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision:

More information

Monitor serum uric acid levels before each infusion. (2.3)

Monitor serum uric acid levels before each infusion. (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KRYSTEXXA safely and effectively. See full prescribing information for KRYSTEXXA KRYSTEXXA (pegloticase

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: [11/2016] FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION. Revised: [11/2016] FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VELTASSA safely and effectively. See full prescribing information for VELTASSA. VELTASSA (patiromer)

More information

2 DOSAGE AND ADMINISTRATION 2.1 Dosing and Dose Adjustment

2 DOSAGE AND ADMINISTRATION 2.1 Dosing and Dose Adjustment HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Auryxia safely and effectively. See full prescribing information for Auryxia. Auryxia (ferric citrate)

More information

Description of Commitment

Description of Commitment U.S. Postmarketing s Table: Name of Product ANDROGEL (testosterone) CREON (pancrelipase) CREON (pancrelipase) DEPAKOTE (divalproex sodium) NDA/ NDA 22309 NDA 20725 NDA 20725 NDA 22267 125057/0 125057/89

More information

MK 0954 PAGE 5 LOSARTAN POTASSIUM RISK MANAGEMENT PLAN, VERSION 4.0

MK 0954 PAGE 5 LOSARTAN POTASSIUM RISK MANAGEMENT PLAN, VERSION 4.0 MK 0954 PAGE 5 LOSARTAN POTASSIUM 2.0 ELEMENTS FOR A PUBLIC SUMMARY 2.1 Overview of disease epidemiology High blood pressure, also known as hypertension, occurs in a large percentage of the adult population.

More information

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety,

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate

More information

Ipratropium bromide/salbutamol

Ipratropium bromide/salbutamol Ipratropium bromide VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD): Chronic obstructive pulmonary disease (COPD) is an umbrella

More information

Drug Coding and CPT (Current Procedural Terminology) Guidance

Drug Coding and CPT (Current Procedural Terminology) Guidance Aridol (mannitol inhalation powder) Bronchial Challenge Test Kit NDC 44178-0552-1 Drug Coding and CPT (Current Procedural Terminology) Guidance Product Reimbursement Code: HCPCS Code 1 Description 1 J7665

More information

Keeping track of your numbers

Keeping track of your numbers Keeping track of your numbers If you have relapsed or refractory multiple myeloma, keeping track of your numbers can help you take an active role in your care. It s also one way you and your doctor can

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

More information

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5 European Medicines Agency July 1996 CPMP/ICH/140/95 ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals Step 5 NOTE FOR GUIDANCE ON THE NEED FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS

More information

PRODUCT INFORMATION Vita-B12 Injection 1mg/1mL

PRODUCT INFORMATION Vita-B12 Injection 1mg/1mL PRODUCT INFORMATION Vita-B12 Injection 1mg/1mL NAME OF THE MEDICINE Hydroxocobalamin (as acetate) Chemical structure Hydroxocobalamin acetate has the following chemical structure: CAS number 22465-48-1

More information

Package Insert. Product Summary. 1. Name of the medicinal product

Package Insert. Product Summary. 1. Name of the medicinal product Package Insert Renerve Injection Product Summary 1. Name of the medicinal product Renerve Injection 2. Qualitative and quantitative composition Each 1 ml contains: Mecobalamin I.P. 1000 mcg. 3. Pharmaceutical

More information

Arikace -Liposomal Amikacin: Preclinical Summary

Arikace -Liposomal Amikacin: Preclinical Summary Arikace -Liposomal Amikacin: Preclinical Summary Arikace is a sustained-release lipid formulation of amikacin for inhalation, being developed for lung infections due to susceptible pathogens Key Features

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GUIDELINE ON THE NEED FOR CARCINOGENICITY STUDIES

More information

PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous injection Initial U.S. Approval: 2014

PLEGRIDY (peginterferon beta-1a) injection, for subcutaneous injection Initial U.S. Approval: 2014 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PLEGRIDY safely and effectively. See full prescribing information for PLEGRIDY. PLEGRIDY (peginterferon

More information

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension

VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension VISTARIL (hydroxyzine pamoate) Capsules and Oral Suspension DESCRIPTION Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4- [2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1

More information

ALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No.

ALLERGENIC EXTRACT. Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE. U.S. Government License No. ALLERGENIC EXTRACT Prescription Set of Serial Dilutions (or Maintenance Vial (s)) INSTRUCTIONS FOR USE U.S. Government License No. 308 Revised 07/04 PO Box 800 Lenoir, NC 28645 USA DESCRIPTION This set

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start

More information

BILLING AND CODING INFORMATION

BILLING AND CODING INFORMATION Effective April 1, 2016, C-Code for Portrazza: C9475, Injection, necitumumab, 1 mg BILLING AND CODING INFORMATION INDICATION Portrazza (necitumumab) is an epidermal growth factor receptor (EGFR) antagonist

More information

0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container

0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container Page 1 of 8 PRESCRIBING INFORMATION 0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of

More information

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP

PHENYLEPHRINE HYDROCHLORIDE INJECTION USP PRESCRIBING INFORMATION PHENYLEPHRINE HYDROCHLORIDE INJECTION USP 10 mg/ml Sandoz Canada Inc. Date of Preparation: September 1992 145 Jules-Léger Date of Revision : January 13, 2011 Boucherville, QC, Canada

More information

Nebulized Colistimethate (Coly-Mycin ) or Colistin

Nebulized Colistimethate (Coly-Mycin ) or Colistin Nebulized Colistimethate (Coly-Mycin ) or Colistin Indication for use of this Medicine Colistimethate is used to treat lung infections caused by Pseudomonas, a type of bacteria. Dose - Either 75 mg or

More information

RUCONEST : IMMUNOLOGICAL ASSESSMENTS NON-PROMOTIONAL EDUCATIONAL MATERIALS FOR PRESCRIBERS

RUCONEST : IMMUNOLOGICAL ASSESSMENTS NON-PROMOTIONAL EDUCATIONAL MATERIALS FOR PRESCRIBERS RUCONEST : IMMUNOLOGICAL ASSESSMENTS NON-PROMOTIONAL EDUCATIONAL MATERIALS FOR PRESCRIBERS Summary Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor (rhc1inh), is derived from milk of

More information

New Zealand Consumer Medicine Information

New Zealand Consumer Medicine Information New Zealand Consumer Medicine Information Actilyse Alteplase What is in this leaflet This leaflet answers some common questions about Actilyse. It does not contain all available information. It does not

More information

Starting treatment early with PERJETA

Starting treatment early with PERJETA Starting treatment early with PERJETA A TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER GIVEN BEFORE SURGERY HER2 = human epidermal growth factor receptor 2. What does PERJETA treat? PERJETA (pertuzumab)

More information

Core Safety Profile. Pharmaceutical form(s)/strength: Nasal suspension, 50mcg UK/H/PSUR/0041/001 Date of FAR:

Core Safety Profile. Pharmaceutical form(s)/strength: Nasal suspension, 50mcg UK/H/PSUR/0041/001 Date of FAR: Core Safety Profile Active substance: Mometasone Pharmaceutical form(s)/strength: Nasal suspension, 50mcg P-RMS: UK/H/PSUR/0041/001 Date of FAR: 17.06.2010 4.3 Contraindications / / (mometasone furoate)

More information

Gaucher Personal Support (GPS) Your one-stop resource for support

Gaucher Personal Support (GPS) Your one-stop resource for support Gaucher Personal Support (GPS) Your one-stop resource for support Connect with Gaucher Personal Support (GPS) today Welcome to GPS, a one-stop resource for support for the Gaucher community, brought to

More information

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011). Page 1 of 10 ANALYTE NAME AND STRUCTURE TERIFLUNOMIDE Teriflunomide TRADE NAME Aubagio CATEGORY Antimetabolite TEST CODE PURPOSE Therapeutic Drug Monitoring GENERAL RELEVANCY BACKGROUND sclerosis. The

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NUCALA safely and effectively. See full prescribing information for NUCALA. NUCALA (mepolizumab)

More information

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Session 6 Clinical Trial Assessment Phase I Clinical Trial L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

NHS FORTH VALLEY. Ferinject in Pregnancy

NHS FORTH VALLEY. Ferinject in Pregnancy NHS FORTH VALLEY Ferinject in Pregnancy Date of First Issue 23/10/2014 Approved 01/10/2014 Current Issue Date 23/10/2014 Review Date 23/10/2016 Version 1.0 EQIA Yes 23/10/2014 Author / Contact Debbie Forbes

More information

Annex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation

Annex II. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation Annex II Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation 7 Scientific conclusions Overall summary of the scientific evaluation of Cymevene i.v. and associated

More information

Nucala. (mepolizumab) New Product Slideshow

Nucala. (mepolizumab) New Product Slideshow Nucala (mepolizumab) New Product Slideshow Introduction Brand name: Nucala Generic name: Mepolizumab Pharmacological class: Interleukin-5 antagonist Strength and Formulation: 100mg per vial; lyophilized

More information

5.07.09. Aubagio. Aubagio (teriflunomide) Description

5.07.09. Aubagio. Aubagio (teriflunomide) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)

More information

ENDOTRACHEAL TUBE LENGTH CHART*

ENDOTRACHEAL TUBE LENGTH CHART* ENDOTRACHEAL TUBE LENGTH CHART* WEIGHT RANGE 3000 g ET TUBE SIZE DEPTH OF ORAL INSERTION 2.5 mm 3 mm 3.5 mm 4 mm 6-7 cm 7-8 cm 8-9 cm 9-11 cm *Adapted from Oakes DF. Oakes

More information

XOLAIR [omalizumab] For injection, for subcutaneous use Initial U.S. Approval: 2003 WARNING: ANAPHYLAXIS

XOLAIR [omalizumab] For injection, for subcutaneous use Initial U.S. Approval: 2003 WARNING: ANAPHYLAXIS HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. XOLAIR [omalizumab] For injection,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin. Albuman 200 g/l SPC 01 December 2015 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Albuman 200 g/l solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Albuman 200 g/l

More information

Product Information HYDROXO-B12

Product Information HYDROXO-B12 Product Information HYDROXO-B12 Name of medicine Hydroxocobalamin ( ) as chloride. Molecular formula: C 62 H 90 ClCoN 13 O 15 P. Molecular weight is 1,383. CAS: 58288-50-9. Description Hydroxocobalamin

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol

PACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol PACKAGE LEAFLET: INFORMATION FOR THE USER PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion Paracetamol Read all of this leaflet carefully before you start using this medicine. Keep this leaflet.

More information

ATROVENT HFA (ipratropium bromide HFA) Inhalation Aerosol FOR ORAL INHALATION ONLY. Initial U.S. Approval: 2004

ATROVENT HFA (ipratropium bromide HFA) Inhalation Aerosol FOR ORAL INHALATION ONLY. Initial U.S. Approval: 2004 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ATROVENT HFA safely and effectively. See full prescribing information for ATROVENT HFA. ATROVENT

More information

VITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1 Ampul

VITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1 Ampul VITAMIN K 1 INJECTION Phytonadione Injectable Emulsion, USP Aqueous Dispersion of Vitamin K 1 Ampul R x only Protect from light. Keep ampuls in tray until time of use. WARNING INTRAVENOUS AND INTRAMUSCULAR

More information

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa)

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa) MEDICATION GUIDE PROCRIT (PROKRIT) (epoetin alfa) Read this Medication Guide: before you start PROCRIT. if you are told by your healthcare provider that there is new information about PROCRIT. if you are

More information

Contact: Rebecca Wong (415) Questions and Answers Regarding Vidaza (azacitidine for injectable suspension) and Demethylating Agents

Contact: Rebecca Wong (415) Questions and Answers Regarding Vidaza (azacitidine for injectable suspension) and Demethylating Agents Contact: Rebecca Wong (415) 278-3319 Questions and Answers Regarding Vidaza (azacitidine for injectable suspension) and Demethylating Agents The recent approval of a third drug for the treatment of MDS

More information

INFUSE Bone Graft. Patient Information Brochure

INFUSE Bone Graft. Patient Information Brochure INFUSE Bone Graft Patient Information Brochure This Patient Guide is designed to help you decide whether or not to have surgery using INFUSE Bone Graft to treat your broken tibia (lower leg). There are

More information

NIZORAL (KETOCONAZOLE) 2% SHAMPOO DESCRIPTION

NIZORAL (KETOCONAZOLE) 2% SHAMPOO DESCRIPTION NIZORAL (KETOCONAZOLE) 2% SHAMPOO DESCRIPTION NIZORAL (ketoconazole) 2% Shampoo is a red-orange liquid for topical application, containing the broad spectrum synthetic antifungal agent ketoconazole in

More information

Cystic Fibrosis and Pulmozyme (dornase alfa), TOBI (tobramycin), and Cayston (aztreonam) Inhalation Solutions

Cystic Fibrosis and Pulmozyme (dornase alfa), TOBI (tobramycin), and Cayston (aztreonam) Inhalation Solutions Cystic Fibrosis and Pulmozyme (dornase alfa), TOBI (tobramycin), and Cayston (aztreonam) Inhalation Solutions What is cystic fibrosis? People with cystic fibrosis have thick, sticky mucus which builds

More information

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only Easyfive Pentavalent Vaccine For Intramuscular Injection only For Active Immunization against Diphtheria, Tetanus, Whooping

More information

NPLATE (romiplostim) for injection, for subcutaneous use Initial U.S. Approval: 2008

NPLATE (romiplostim) for injection, for subcutaneous use Initial U.S. Approval: 2008 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NPLATE safely and effectively. See full prescribing information for NPLATE. NPLATE (romiplostim)

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET MATERIAL SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY Material Manufacturer Distributor Cephalexin Capsules USP 250 mg and 500 mg Lupin Limited Mandideep 462 046 INDIA. Lupin Pharmaceuticals,

More information

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India.

INTRODUCTION TO CLINICAL TRIAL. Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION TO CLINICAL TRIAL Dr.K.T. Manisenthil Kumar, Head, Department of pharmacology, KMCH college of pharmacy, Coimbatore, Tamilnadu, India. INTRODUCTION The safety and toxicity data generated from

More information

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AFREZZA safely and effectively. See full prescribing information for AFREZZA. AFREZZA (insulin human)

More information

Biologic Treatments for Rheumatoid Arthritis

Biologic Treatments for Rheumatoid Arthritis Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been

More information

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS Registration No. 1C 68/47(NC) Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania 19486 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICAL PRODUCT VARIVAX [Varicella

More information

1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%.

1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%. Endotoxicity and Cytotoxicity Studies 1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Chinese Hamster Ovary (CHO) cells were grown in monolayer with and without metabolic activation.

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because

More information

FULL PRESCRIBING INFORMATION: CONTENTS*

FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use REPATHA safely and effectively. See full prescribing information for REPATHA. REPATHA (evolocumab)

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS

PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS PREPARATION AND SELF-ADMINISTRATION INSTRUCTIONS FOR PATIENTS Jeanie, a real HAE patient TAKING CHARGE OF YOUR HEREDITARY ANGIOEDEMA (HAE) TREATMENT WITH SELF-ADMINISTRATION Choosing to self-administer

More information

UNDERSTANDING HAIR THINNING/HAIR LOSS

UNDERSTANDING HAIR THINNING/HAIR LOSS UNDERSTANDING HAIR THINNING/HAIR LOSS INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING: HEPATOTOXICITY

More information

Revised 04/2015 FULL PRESCRIBING INFORMATION: CONTENTS*

Revised 04/2015 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KYBELLA safely and effectively. See full prescribing information for KYBELLA. KYBELLA (deoxycholic

More information